1. Home
  2. NVAX vs DMRA Comparison

NVAX vs DMRA Comparison

Compare NVAX & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$9.32

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

DMRA

Damora Therapeutics Inc. Common Stock

N/A

Current Price

$24.16

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NVAX
DMRA
Founded
1987
2011
Country
United States
United States
Employees
N/A
7
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.6B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
NVAX
DMRA
Price
$9.32
$24.16
Analyst Decision
Hold
Buy
Analyst Count
9
2
Target Price
$11.33
$43.00
AVG Volume (30 Days)
4.9M
283.9K
Earning Date
05-06-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
309.76
N/A
EPS
N/A
N/A
Revenue
$1,123,479,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
64.69
N/A
52 Week Low
$6.20
$16.50
52 Week High
$11.85
$28.76

Technical Indicators

Market Signals
Indicator
NVAX
DMRA
Relative Strength Index (RSI) 55.84 46.42
Support Level $9.14 $22.71
Resistance Level $10.66 $28.00
Average True Range (ATR) 0.68 1.63
MACD 0.03 -0.06
Stochastic Oscillator 50.82 43.57

Price Performance

Historical Comparison
NVAX
DMRA

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

About DMRA Damora Therapeutics Inc. Common Stock

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Share on Social Networks: